Open AccessComplete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and “BRCAness” Mutations
Author(s) -
Sanghee Hong,
Pauline Funchain,
Abdo Haddad,
Joseph P. Crowe,
Nancy Dalpiaz,
Jame Abraham
Publication year - 2016
Publication title -
journal of oncology practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.555
H-Index - 60
eISSN - 1935-469X
pISSN - 1554-7477
DOI - 10.1200/jop.2016.010710
Subject(s) - olaparib , medicine , triple negative breast cancer , carboplatin , brca mutation , parp inhibitor , germline , metastatic breast cancer , oncology , germline mutation , cancer research , triple negative , breast cancer , ovarian cancer , mutation , cancer , poly adp ribose polymerase , chemotherapy , genetics , gene , polymerase , biology , cisplatin
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom